1. Home
  2. QNCX

as 11-21-2024 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Founded: 2012 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 34.4M IPO Year: 2019
Target Price: $9.67 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.25 EPS Growth: N/A
52 Week Low/High: $0.51 - $2.14 Next Earning Date: 11-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

QNCX Daily Stock ML Predictions

Stock Insider Trading Activity of Quince Therapeutics Inc. (QNCX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Thye Dirk QNCX CEO AND CHIEF MEDICAL OFFICER Aug 29 '24 Buy $0.70 154,500 $107,375.00 766,941

Share on Social Networks: